{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T20:38:27Z","timestamp":1649104707769},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.medcli.2012.03.032","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T10:45:21Z","timestamp":1340793921000},"page":"373-378","source":"Crossref","is-referenced-by-count":2,"title":["Impacto cl\u00ednico de la cuantificaci\u00f3n de la carga mutacional de JAK2V617F en pacientes con neoplasias mieloproliferativas cr\u00f3nicas Ph negativas cl\u00e1sicas"],"prefix":"10.1016","volume":"139","author":[{"given":"Ana Esther","family":"Kerguel\u00e9n Fuentes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Hern\u00e1ndez-Maraver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Lombardia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"Canales Albendea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Rodriguez de la R\u00faa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2012.03.032_bib0005","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.medcli.2012.03.032_bib0010","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2012.03.032_bib0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.03.032_bib0020","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.03.032_bib0025","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.03.032_bib0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1050-3862(98)00019-9","article-title":"Allelic discrimination using fluorogenic probes and the 5\u2019 nuclease assay","volume":"14","author":"Livak","year":"1999","journal-title":"Genet Anal"},{"key":"10.1016\/j.medcli.2012.03.032_bib0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.03.032_bib0040","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1157\/13094416","article-title":"[Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders]","volume":"127","author":"Remacha","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2012.03.032_bib0045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jmoldx.2011.05.007","article-title":"Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology","volume":"13","author":"Tefferi","year":"2011","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.medcli.2012.03.032_bib0050","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.03.032_bib0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ajh.21183","article-title":"Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy","volume":"83","author":"Tefferi","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.medcli.2012.03.032_bib0060","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2012.03.032_bib0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2012.03.032_bib0070","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2012.03.032_bib0075","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.03.032_bib0080","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1538-7836.2009.03531.x","article-title":"Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia","volume":"7","author":"Passamonti","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.medcli.2012.03.032_bib0085","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.03.032_bib0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF03324948","article-title":"JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia","volume":"23","author":"Randi","year":"2011","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.medcli.2012.03.032_bib0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia","volume":"33","author":"Dahabreh","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2012.03.032_bib0100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.medcli.2012.03.032_bib0105","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.medcli.2012.03.032_bib0110","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2012.03.032_bib0115","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.03.032_bib0120","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2141.2009.07804.x","article-title":"Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients","volume":"146","author":"Alvarez-Larr\u00e1n","year":"2009","journal-title":"Br J Haematol"},{"issue":"1 Suppl 1","key":"10.1016\/j.medcli.2012.03.032_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/shem.2003.50026","article-title":"Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry","volume":"40","author":"Spivak","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.medcli.2012.03.032_bib0130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1179\/102453309X12473408860226","article-title":"Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders","volume":"14","author":"Basquiera","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.medcli.2012.03.032_bib0135","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.leukres.2006.01.008","article-title":"JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia","volume":"30","author":"Mesa","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.medcli.2012.03.032_bib0140","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.moh.0000208470.86732.b4","article-title":"Essential thrombocythemia: scientific advances and current practice","volume":"13","author":"Tefferi","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.medcli.2012.03.032_bib0145","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2012.03.032_bib0150","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775312004654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775312004654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T14:20:47Z","timestamp":1542896447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775312004654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0025775312004654"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2012.03.032","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}